Vale L, Cody J, Wallace S, Daly C, Campbell M, Grant A, Khan I, Donaldson C, Macleod A
Health Economics Research Unit/Health Services Research Unit, University of Aberdeen, Medical School Building, Foresterhill, Aberdeen, UK, AB25 2ZD.
Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD003963. doi: 10.1002/14651858.CD003963.pub2.
Renal replacement therapy (RRT) with dialysis and transplantation is the only means of sustaining life for patients with end-stage renal disease (ESRD). Although transplantation is the treatment of choice, the number of donor kidneys are limited and transplants may fail. Hence many patients require long-term or even life-long dialysis. Continuous ambulatory peritoneal dialysis (CAPD) is an alternative to hospital or home haemodialysis for patients with ESRD.
To assess the benefits and harms of CAPD versus hospital or home haemodialysis for adults with ESRD.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL in The Cochrane Library), the Cochrane Renal Group's specialised register, MEDLINE (1966 - May 2002), EMBASE (1980 - May 2002), BIOSIS, CINAHL, SIGLE and NRR without language restriction. Reference lists of retrieved articles and conference proceedings were searched and known investigators and biomedical companies were contacted. Date of most recent search January 2004.
Randomised controlled trials (RCTs) or quasi-RCTs comparing CAPD to hospital or home haemodialysis for adults with ESRD were to be included.
Two reviewers independently assess the methodological quality of studies. Data was abstracted from included studies onto a standard form by one reviewer and checked by another. Statistical analyses were performed using the random effects model and the results expressed as relative risk (RR) for dichotomous outcomes and weighted mean difference (WMD) for continuous outcomes with 95% confidence intervals (CI).
One trial, reported in abstract form only, was located in the most recent search. There was no statistical difference in death or quality adjusted life years score at 2 years between peritoneal dialysis or haemodialysis patients.
REVIEWERS' CONCLUSIONS: There is Insufficient data to allow conclusions to be drawn about the relative effectiveness of CAPD compared with hospital or home haemodialysis for adults with ESRD. Efforts should be made to start and complete adequately powered RCTs, which compare the different dialysis modalities.
采用透析和移植的肾脏替代疗法(RRT)是终末期肾病(ESRD)患者维持生命的唯一手段。尽管移植是首选治疗方法,但供体肾脏数量有限,且移植可能失败。因此,许多患者需要长期甚至终身透析。持续性非卧床腹膜透析(CAPD)是ESRD患者医院或家庭血液透析的一种替代方法。
评估CAPD与医院或家庭血液透析相比,对成年ESRD患者的益处和危害。
我们检索了Cochrane对照试验中心注册库(Cochrane图书馆中的CENTRAL)、Cochrane肾脏组的专业注册库、MEDLINE(1966年至2002年5月)、EMBASE(1980年至2002年5月)、BIOSIS、CINAHL、SIGLE和NRR,无语言限制。检索了检索到的文章的参考文献列表和会议论文集,并联系了知名研究人员和生物医学公司。最近一次检索日期为2004年1月。
纳入比较CAPD与医院或家庭血液透析对成年ESRD患者疗效的随机对照试验(RCT)或半随机对照试验。
两名评价员独立评估研究的方法学质量。由一名评价员将纳入研究的数据提取到标准表格中,另一名评价员进行核对。采用随机效应模型进行统计分析,结果以二分结局的相对危险度(RR)和连续结局的加权均数差(WMD)表示,并给出95%置信区间(CI)。
在最近的检索中仅找到一篇以摘要形式报道的试验。腹膜透析或血液透析患者在2年时的死亡或质量调整生命年评分无统计学差异。
尚无足够数据得出关于CAPD与医院或家庭血液透析相比对成年ESRD患者相对有效性的结论。应努力启动并完成有足够样本量的RCT,以比较不同的透析方式。